Vaccination Status – Page 12 – Communicable Diseases Research

Symptoms and SARS-CoV-2 positivity in the general population in the UK

영국 일반 인구의 증상 및 SARS-CoV-2 양성

Major Article

Published on 2021-11-082022-09-10
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 치료기술, 치료제,

569. Characterization of COVID-19 Vaccine Breakthrough Infections in Metropolitan Detroit

Poster Abstracts

Published on 2021-11-042022-10-29
Journal: Open Forum Infectious Diseases [Category] COVID-19,

[키워드] Antigen Asymptomatic asymptomatic patients Breakthrough infection Care CDC center characterization Control COVID-19 COVID-19 illness COVID-19 vaccine Critical Detroit died discharged disease severity dose effective Effectiveness electronic medical record evaluate female HCW Healthcare system healthcare worker heart failure Henry Ford Hospitalization identify Immunocompromised Intensive majority median age Mortality occur one patient Patient patient population patients reduced reported required respiratory sample Result retrospective SARS-CoV-2 RNA SARS-CoV-2 vaccine symptomatic System the vaccine Vaccination Status Vaccine vaccine breakthrough infection was used
[DOI] 10.1093/ofid/ofab466.767 PMC 바로가기 [Article Type] Poster Abstracts

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada

새로운 SARS-CoV-2 변이체의 상대적 독성 평가: 캐나다 온타리오주에서의 후향적 코호트 연구

Observational Study

Published on 2021-10-252022-09-11
Journal: CMAJ : Canadian Medical Association journal = jour [Category] SARS, 변종, 임상,

[키워드] 95% CI 95% confidence interval absence adjusted Admission age Beta Canada Cohort Comorbidities Comorbidity COVID-19 case death delta variant evaluate health unit health units Hospitalization ICU ICU admission Increased increased risk initial intensive care intensive care unit knowledge logistic regression model N501Y N501Y mutation occurred outcome pandemic positive Pregnancy PREGNANCY STATUS random intercepts retrospective cohort retrospective cohort study risk SARS-CoV-2 SARS-CoV-2 strains screened Sex tested Transmissibility vaccination Vaccination Status variables variant variants variants of concern virulence VoC VOCs wild-type strain
[DOI] 10.1503/cmaj.211248 PMC 바로가기 [Article Type] Observational Study

Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review

SARS-CoV-2 감염 후유증의 단기 및 장기 비율 A 체계적인 검토

Research

Published on 2021-10-132022-09-10
Journal: JAMA Network Open [Category] MERS, 변종,

[키워드] Abnormalities abnormality acute COVID-19 affected age Anxiety Anxiety Disorder cardiovascular Care chest imaging children Clinical sign Clinical signs Cohort studies contributed coronavirus coronavirus disease country COVID-19 COVID-19 infection database databases dependent on diagnosed DIFFICULTY CONCENTRATING digestive disorder disorders Effect estimate evaluated Evolution fatigue finding Frequency functional Generalized Anxiety Disorder Health Health care health care systems Health Organization Hospitalized impairment Importance incidence inclusion criteria Infection involved IQR item laboratory investigation literature male median mental health mental health disorders meta-analyses MOST muscle weakness neurologic disorders Newcastle-Ottawa Scale nose objective occur organ organ system organ systems Other outcome PASC pathology performed Point prevalent PRISMA proportion Quality radiologic Rate Relevance reported symptom Reporting review SARS-CoV-2 searched Signs and symptoms survivor Symptom Symptoms systematic review systematic reviews the Newcastle-Ottawa Scale tissue vaccination Vaccination Status variant virus weakness World Health Organization
[DOI] 10.1001/jamanetworkopen.2021.28568 PMC 바로가기 [Article Type] Research

Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans

미국 제대군인 중 mRNA COVID-19 백신의 적용 범위 및 예상 효과

Research

Published on 2021-10-062022-09-10
Journal: JAMA Network Open [Category] MERS, SARS, 변종,

[키워드] 95% CI 95% CIs Alpha analyzed Antigen association black Care case-control study Chain Reaction Comorbidity conducted Control controls Coverage COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine death defined discharge Effectiveness Electronic health record Electronic health records Epsilon estimate Estimated exposure finding first dose health administration Hispanic Hospitalization Importance increase in Infection Iota measure men mRNA mRNA vaccination objective Odds ratio Odds ratios older population outcome participant Point polymerase chain polymerase chain reaction positive positive result positive test result Racial reductions reductions in Relevance Result risk of COVID-19 rural areas SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 test SARS-CoV-2 variant SARS-CoV-2 variants second dose secondary Secondary outcomes setting subgroup subpopulation subpopulations Symptoms test result test results urban vaccination Vaccination Status Vaccine veteran veterans white
[DOI] 10.1001/jamanetworkopen.2021.28391 PMC 바로가기 [Article Type] Research

Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies

미국 교도소 내 COVID-19 변종 발병: 예방 접종 및 재개방 정책에 대한 수학적 모델링 분석

Article

Published on 2021-10-012022-09-11
Journal: The Lancet. Public Health [Category] SARS, 변종,

[키워드] Abuse activities activity age Analysis balancing baseline benefit Cell center Characteristics Contact Control Coverage COVID-19 COVID-19 outbreak COVID-19 testing cumulative demographics dependent on disease control drug Drug Abuse evaluate expected family FIVE foundation Health Horowitz hospitalisation hospitalisations housing status Immunity Infection initial Intervention introduced maintain Mathematical modelling measure moderate NPI NPIs Open society outbreak Outbreaks outcome Participation populations prevention prison proliferate PROTECT provided reduce repeated resident risk scenario Science Society Sociodemographic trade-offs Transmission USA vaccination Vaccination Status Vaccine variant viral variant Viral variants widespread
[DOI] 10.1016/S2468-2667(21)00162-6 PMC 바로가기 [Article Type] Article

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study

광저우에서 델타 변이 감염에 대한 비활성화된 SARS-CoV-2 백신의 효과: 테스트 음성 사례-대조군 실제 연구

Research Article

Published on 2021-09-022022-09-10
Journal: Emerging Microbes & Infections [Category] SARS, 변종,

[키워드] 95% confidence interval age and sex China conducted Control coronavirus disease Coronavirus disease 2019 COVID-19 delta variant Diseases effective Effectiveness Efficacy efficacy of vaccination female greater transmissibility Guangzhou Health Organization inactivated Inactivated vaccine Inactivated Vaccines Infection male moderate Moderate COVID-19 outbreak participant Protective reached recruited SARS-CoV-2 SARS-CoV-2 vaccine severe COVID-19 single dose small sample size the vaccine threshold vaccination vaccination against COVID-19 Vaccination Status Vaccine virulence while World Health Organization
[DOI] 10.1080/22221751.2021.1969291 PMC 바로가기 [Article Type] Research Article

Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study

Research

Published on 2021-08-182022-10-28
Journal: The BMJ [Category] COVID-19, MERS, SARS,

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

B.1.617.2(델타) 변종에 대한 Covid-19 백신의 효과

Article

Published on 2021-08-122022-09-11
Journal: The New England Journal of Medicine [Category] SARS, 변종, 치료기술,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha Alpha variant B.1.1.7 B.1.617.2 BNT162b2 BNT162b2 vaccine Case-control cause caused ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine circulating contributed coronavirus coronavirus disease Coronavirus disease 2019 Delta delta variant dose Effectiveness effort England first dose globe increase in India notable populations predominant proportion Public Public Health England receipt SARS-CoV-2 sequenced Sequencing severe acute respiratory syndrome Coronavirus Support symptomatic symptomatic disease the patient United Kingdom vaccination Vaccination Status Vaccine vaccine doses Vaccines variant variants virus were used
[DOI] 10.1056/NEJMoa2108891 PMC 바로가기 [Article Type] Article

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

다발성 골수종 및 골수증식성 악성종양 환자에 대한 항SARS-CoV-2 BNT162b2 백신의 5주 면역원성 및 활성 치료에 대한 안전성: 단일 기관의 예비 데이터

Clinical Trial

Published on 2021-05-172022-08-13
Journal: Journal of Hematology & Oncology [Category] SARS, 임상, 진단,

[키워드] anti-cancer treatment anti-CD38 anti-SARS-CoV-2 anti-SARS-CoV-2 IgG approved assumed basal BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine booster Cancer chemiluminescent immunoassay chronic myeloid leukemias Cohort cohorts Committee Concentration Concordance Contagion Control Cutoff daratumumab demonstrated disease dose Endpoint evaluated Evidence family family members FDA first dose Gender geometric mean Geometric mean concentrations geometric mean ratio geometric mean ratios GMC GMCs hematological Hematological malignancy IgG IgG test immunogenic immunogenicity increasing age IRCCS Lazio less leukemia likelihood Linear model logarithm maintain Mann–Whitney test Mask Masks mRNA vaccine Multiple myeloma myeloproliferative malignancies myeloproliferative malignancy myeloproliferative neoplasms neutralization test Neutralizing of BNT162b2 Patient patients plaque Plaque reduction neutralization test positive Preliminary data primary endpoint Protective Quantitative reduce Responder responders response response rates Result risk robust S1/S2 Safety SARS-CoV-2 Serologically Seroprotection rate significantly social distancing Swab swabs Test titers titration Treatment vaccination Vaccination Status was done were excluded
[DOI] 10.1186/s13045-021-01090-6 PMC 바로가기 [Article Type] Clinical Trial